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The chemokine receptors CCR5 and CXCR4 are used by human immunodeficiency virus type 1 (HIV-1) in
conjunction with CD4 to infect cells. In addition, some virus strains can use alternative chemokine receptors,
including CCR2b and CCR3, for infection. A polymorphism in CCR2 (CCR2-V64I) is associated with a 2- to
4-year delay in the progression to AIDS. To investigate the mechanism of this protective effect, we studied the
expression of CCR2b and CCR2b-V64I, their chemokine and HIV-1 coreceptor activities, and their effects on
the expression and receptor activities of the major HIV-1 coreceptors. CCR2b and CCR2b-V64I were expressed
at similar levels, and neither molecule affected the expression or coreceptor activity of CCR3, CCR5, or CXCR4
in cotransfected cell lines. Peripheral blood mononuclear cells (PBMCs) from CCR2-V64I heterozygotes had
normal levels of CCR2b and CCR5 but slightly reduced levels of CXCR4. CCR2b and CCR2b-V64I functioned
equally well as HIV-1 coreceptors, and CCR2-V64I PBMCs were permissive for HIV-1 infection regardless of
viral tropism. The MCP-1-induced calcium mobilization mediated by CCR2b signaling was unaffected by the
polymorphism, but MCP-1 signaling mediated by either CCR2b- or CCR2-V64I-encoded receptors resulted in
heterologous desensitization (i.e., limiting the signal response of other receptors) of both CCR5 and CXCR4.
The heterologous desensitization of CCR5 and CXCR4 signaling by both CCR2 allele receptor types provides
a mechanistic link that might help explain the in vivo effects of CCR2 gene variants on progression to AIDS as
well as the reported antiviral activity of natural CCR2 ligands.
including CCR2b and CCR3 (16, 22, 26, 50). Evolution of
coreceptor use in vivo from CCR5 to additional coreceptors
has been linked to disease progression and may help explain
certain aspects of viral pathogenesis (18, 52).
The importance of CCR5 for viral transmission is shown by
the fact that approximately 1% of Caucasians are CCR5 negative due to a naturally occurring polymorphism and that these
individuals are very highly resistant to virus infection (20, 35,
39, 51). The critical role of CCR5 for viral transmission and the
association between the emergence of viruses that use CXCR4
and accelerated disease progression has triggered a search for
additional polymorphisms in chemokine receptor genes that
may influence viral transmission and disease course. Recently,
a polymorphism in CCR2 in which Val 64 is replaced by Ile
(CCR2-V64I) has been reported (55). This polymorphism,
which occurs at an allele frequency of 10 to 25%, depending on
the ethnic population, is associated with a 2- to 4-year delay in
the progression to AIDS. However, relatively few virus strains
that can use CCR2b in conjunction with CD4 to infect cells
have been reported (22). Therefore, the mechanism underlying
this protective effect is not apparent.
To investigate the protective effect of the CCR2 polymorphism, we studied the expression as well as the chemokine
receptor and HIV-1 coreceptor activities of the major CCR2
isoform, CCR2b, with and without the V64I mutation in peripheral blood mononuclear cells (PBMCs) and transfected
cell lines. CCR2b-V64I was expressed at levels similar to

Infection of cells by human immunodeficiency virus type 1
(HIV-1) requires the presence of the viral receptor CD4 and
an appropriate coreceptor on the cell surface. Direct interactions between the viral Env protein and the coreceptor are
thought to trigger conformational changes in Env that lead to
fusion between the viral and cellular membranes, allowing the
viral genome to enter the host cell cytoplasm (reviewed in
references 7, 10, 12, 23, and 43). The recent identification of
certain chemokine receptors as coreceptors for HIV-1, HIV-2,
and simian immunodeficiency virus (SIV) has provided tremendous insight into the mechanisms underlying viral entry
and tropism. The virus strains responsible for transmission and
which are the predominant virus type isolated from asymptomatic, HIV-positive individuals use CCR5 as a coreceptor, while
viruses that emerge later during the course of infection use
CXCR4 either in place of or in addition to CCR5 for cellular
entry (2, 9, 16, 21, 26, 27, 31). By virtue of their differential use
of the major HIV-1 coreceptors, it has been proposed that
these viruses be referred to as R5, X4, and R5X4 strains,
respectively (8, 22). In addition, a host of other chemokine and
orphan seven-transmembrane domain receptors have been
shown to support infection by one or more virus strains in vitro,
* Corresponding author. Mailing address: Department of Pathology
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34th and Civic Center Blvd., Philadelphia, PA 19104. Phone: (215)
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MATERIALS AND METHODS
Cells. Heparinized whole blood was collected from healthy volunteers previously screened by PCR-restriction fragment length polymorphism (RFLP) for
the CCR2b-V64I mutation (see below). Unstimulated PBMCs were isolated by
Ficoll-Hypaque gradient centrifugation (Pharmacia Biotech, Uppsala, Sweden)
and placed in RPMI 1640 (GibcoBRL, Grand Island, N.Y.) supplemented with
10% fetal calf serum (GibcoBRL) and allowed to recover in media at 37°C for
6 h before staining for fluorescence-activated cell sorting (FACS) analyses. We
also stained PBMCs in whole blood followed by selective erythrocyte lysis using
PharM Lyse according to the manufacturer’s directions (Pharmingen, San Diego,
Calif.) to determine if the way in which PBMCs were isolated affected coreceptor
expression levels. PBMCs were considered stimulated if they were first cultured
in medium supplemented with phytohemagglutinin (PHA) for 2 days followed by
3 days in recombinant interleukin-2 (IL-2; 100 U/ml) (called PHA/IL-2 treatment) before FACS analysis was performed. 239T cells and quail QT6 cells were
cultured in Dulbecco’s minimal essential medium (GibcoBRL) supplemented
with 10% fetal calf serum, 2 mM glutamine, and 2 mM penicillin-streptomycin.
Antibodies. Monoclonal antibodies (MAbs) used in FACS analyses against
CCR2b, CCR3, CCR5, and CXCR4 were R02 (biotinylated) (32), 7B11 (NIH
AIDS Reference and Reagent Program), clone 45549 (R&D Systems, Minneapolis, Minn.), and 12G5 (29), respectively.
Plasmids and viruses. Plasmids encoding the HIV-1 ADA, HxB2, and NL4-3
Envs for use in making luciferase virus were provided by John Moore (Aaron
Diamond AIDS Research Center). The NL4-3 luciferase virus backbone (pNLluc-E2R2) was provided by Ned Landau (Aaron Diamond AIDS Research
Center) (15, 17). The plasmid expressing the CCR2b-V64I variant was cloned
from an CCR2-V64I/V64I individual by using primers to amplify a 412-bp fragment from the 59 end of the CCR2b gene encompassing the V64I mutation. The
upstream primer introduces a HindIII site, while the downstream primer encompasses the unique ClaI site at position 407 (counting from the ATG start codon)
of CCR2b. This PCR fragment was used to replace the identical HindIII-ClaI
fragment save for the V64I mutation in pcDNA3-CCR2b, previously cloned from
a wild-type CCR2b individual (26). The regenerated pcDNA3-CCR2b-V64I plasmid was confirmed to possess the V64I mutation by restriction mapping and
direct sequencing. All other plasmids have been described by our lab previously
(50). Vaccinia viruses encoding HIV-1 Envs included vSC60 (BH8), vCB51
(BK132; provided by Chris Broder), and vBD3 (89.6). We also used the recombinant virus vTF1.1, encoding the T7 RNA polymerase (1).
PCR-RFLP detection of CCR2b-V64I. The G3A nucleotide substitution at
position 190 (counting from the ATG start codon) resulting in the V64I mutation
also introduces an additional FokI site into the open reading frame of the CCR2b
gene. Genomic DNA was isolated from buccal swabs by incubating samples with
DNA lysis buffer as previously described (47), subjected to 35 cycles of amplification by using Taq polymerase (95°C for 30 s, 62°C for 30 s, and 72°C for 30 s),
separated on a 3% agarose gel, and stained with ethidium bromide. Primers were
designed to amplify a 521-bp fragment from the Kozak sequence immediately
upstream of the ATG codon to position 516 of the CCR2b gene. The amplified
fragment comprises either one FokI site at position 379 in wild-type CCR2b or an
additional FokI site at position 175 in CCR2b-V64I. Restriction digestion of this
fragment with FokI results in either two fragments of 384 and 137 bp when
amplified from a CCR2-1/1 individual or three fragments of 204, 180, and 137
bp when amplified from a CCR2-V64I/V64I individual (2/2). Restriction digestion of PCR fragments from heterozygous individuals (CCR2-1/V64I) results in
four bands of 384, 204, 184, and 134 bp. The presence of at least one FokI site

in the PCR fragment serves as an internal control for enzyme activity and
digestion completion.
Cell-cell fusion and virus infection assays. The efficiency of Env-mediated
cell-cell fusion was determined by a gene reporter assay as described previously
(45, 49). Briefly, 293T effector cells expressing vaccinia virus-driven Env and T7
RNA polymerase were mixed with quail QT6 cells transiently expressing CD4
and the indicated coreceptor with the reporter luciferase gene under control of
the T7 promoter. Cytoplasmic mixing as a result of Env-mediated membrane
fusion results in luciferase production which can be readily quantified with a
luminometer.
Luciferase reporter viruses were prepared as previously described (15, 17) by
cotransfecting 293T cells with the indicated Envs and the NL4-3 luciferase virus
backbone (pNL-luc-E2R2). Target cells were prepared by transfecting U87-MG
cells with CD4 and the appropriate coreceptors or mix of coreceptors as indicated. A constant amount of DNA was used for all target cell transfections by
using pcDNA3 vector as a filler. Four days postinfection, cells were lysed with
0.5% Triton X-100 in phosphate-buffered saline (PBS), and an appropriate
aliquot was analyzed for luciferase activity.
To measure viral entry, pcDNA3, pcDNA3-CCR5, pcDNA3-CXCR4,
pcDNA3-CCR2b, and pcDNA3-V64I were transfected (2 mg of each plasmid)
into 105 CD4-expressing QT6 (QT6/CD4) cells in 48-well tissue culture plates,
using calcium phosphate precipitation. Four hours later, the cells were washed
and placed in fresh medium; 48 h later, cells were infected with DNase-treated
(50 U/ml for 30 min at room temperature) cell-free virus, using 50 ng of viral p24.
After 2 days, cells were washed three times, suspended in 50 ml of lysis buffer
(100 mM KCl, 20 mM Tris [pH 8.4], 0.1% Nonidet P-40, 0.5 mg of proteinase K
per ml), incubated for 2 h at 60°C, and the boiled for 15 min. HIV-1-specific
DNA sequences were detected by PCR using 35 cycles on 2.5 ml of cell lysate to
amplify a 430-bp region of U3/U5 long terminal repeat (LTR) DNA sequences,
using primers LTR-plus/LTR-minus (59-ACAAGCTAGTACCAGTTGAGCC39/59-CACACACTACTTGAAGCACTCA-39). Fourfold serial dilutions of cell
lysate were used under the same conditions. Products were resolved by electrophoresis on 2% agarose gels, transferred to Hybond N1 (Amersham), and
detected by using a 39-End Labeling Biotin kit (DuPont; probe 59-ATCTACA
AGGGACTTTCCCGC-39), followed by exposure.
Calcium mobilization assays. Response to ligand was determined in transiently transfected human 293T cells. Cells were transfected with the desired
coreceptor for 4 to 6 h, medium was replaced, and cells were allowed to express
the coreceptor overnight. Cells were incubated in medium containing 2.5 mM
Fura-2/AM (Molecular Probes) at 37°C in the dark for 1 h. Cell efflux was
allowed to occur for 15 min in PBS before the cells were removed from the plate
manually. The cells were centrifuged and resuspended in Dulbecco’s PBS containing calcium and magnesium (BioWhittaker) at 2 3 106 cells/ml and were
warmed at 37°C for 10 min before measurement of ligand response. Ca21
mobilization was measured in an Aminco-Bowman luminescence spectrometer
in a constantly stirring cuvette and in a volume of 1.5 ml. Excitation of cells was
monitored at 340 and 380 nm, and Ca21 concentration was calculated as previously described, using an assumed molecular weight of 224 (34). MCP-1, RANTES, and SDF-1a were obtained from Peprotech and resuspended in PBS for
use. All cells were also stimulated with 27 mM thrombin receptor agonist peptide
(TAP), consisting of the amino acids SFLLRN, to confirm the integrity of cells
by their ability to signal through the G-protein-coupled receptor PAR-1.
FACS analyses. For analysis of coreceptor expression on PBMCs, fresh or
stimulated PBMCs prepared as described above were stained with primary antibodies for CCR2 (R02), CCR5 (45549), or CXCR4 (12G5) at 10 mg/ml followed by secondary detection by either phycoerythrin-conjugated streptavidin
(2.5 mg/ml; Pharmingen) for anti-CCR2b antibody or affinity-purified phycoerythrin-conjugated donkey anti-mouse antibody (1:100 dilution; Jackson ImmunoResearch Laboratories) for anti-CCR5 or anti-CXCR4 antibody. Analyses
were performed only on the lymphocyte gate defined by broad forward scatter
but low side scatter. The mean channel fluorescence (MCF) was used to compare
the levels of coreceptor expression. For analysis of coreceptor expression on
transfected cells, 293T cells were variously transfected (via CaPO4 precipitation)
with CCR5, CCR3, and CXCR4 plasmids alone or in combination with either
wild-type CCR2b or CCR2b-V64I plasmids, using a constant amount of DNA
with pcDNA3 vector as a filler. Cells were allowed to express the coreceptor for
18 h and subsequently stained with the appropriate anticoreceptor antibodies
followed by secondary detection as described above for the PBMCs. All staining
and washing protocols have been described in detail elsewhere (50), and FACS
analyses were performed on a Becton Dickinson FACScan using the CellQuest
version 3 software (Becton Dickinson, San Jose, Calif.).

RESULTS
Effects of CCR2b-V64I on HIV-1 coreceptor expression. Before studying the chemokine receptor and HIV-1 coreceptor
activities of CCR2-V64I, we determined whether the mutant
receptor was expressed on the cell surface as efficiently as
CCR2b since surface expression levels can strongly influence
coreceptor function (38, 46, 50). Human 293T cells were trans-
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CCR2b in cell lines and in PBMCs, and both functioned
equally well as viral coreceptors. The CCR2b polymorphism
did not affect CCR5 or CXCR4 coreceptor activity or expression levels in cell lines or in stimulated PBMCs, though unstimulated PBMCs from CCR2b-V64I heterozygotes had
slightly reduced CXCR4 levels. The addition of the CCR2b
ligand MCP-1 lead to reduction of (i.e., desensitized) subsequent signaling induced by addition of RANTES, a CCR5
ligand. Similarly, heterologous desensitization of CXCR4 by
CCR2b was observed. By contrast, RANTES and SDF-1 only
partially suppressed subsequent signaling mediated by MCP-1
and CCR2b. Together, these results suggest that the protective
effects of CCR2-V64I are apt to be subtle and indirect. Since
HIV-1 Env has been shown to induce intracellular signals
mediated by either CXCR4 or CCR5 (19, 57), and receptor
signaling may play a role in both receptor surface expression
and postentry events in viral replication (13, 28), this mechanistic link between CCR2b and the major HIV-1 coreceptors
provides a possible explanation for the antiviral effects reported for CCR2b ligands.

7451

7452

LEE ET AL.

J. VIROL.

fected with plasmids encoding either CCR2b or CCR2b-V64I.
CCR2b is the major CCR2 isoform derived by alternative RNA
splicing (14). The plasmids were identical in both coding and
noncoding regions save for the V64I alteration. Expression of
both receptors on the cell surface was determined by FACS
analysis using a previously described MAb to CCR2b (32). We
found that the expression of CCR2b and CCR2b-V64I did not
differ substantially when MCF intensities were compared (Fig.
1A). To determine if the V64I mutation could affect surface
expression levels of other HIV-1 coreceptors, we coexpressed
CCR2b and CCR2b-V64I with CCR5 (Fig. 1B), CXCR4 (Fig.
1C), or CCR3 (Fig. 1D) and measured their surface expression
levels by using well-characterized MAbs. We found no differential effects on the surface expression levels of CCR3, CCR5,
or CXCR4 as a consequence of either CCR2b or CCR2b-V64I
coexpression. Thus, CCR2b-V64I is expressed as well as

CCR2b and, relative to CCR2b, has no effect on the expression
of other HIV-1 coreceptors in transfected 293T cells.
Effects of CCR2b-V64I on HIV-1 coreceptor activity. Since
CCR2b-V64I was expressed normally, we next tested its HIV-1
coreceptor activity by using two different assays. Since only a
handful of viruses that can use CCR2b as a coreceptor have
been identified (22), we also asked if the V64I mutation affects
the coreceptor activity of CCR3, CCR5, or CXCR4. To do this,
we first used a quantitative cell-cell fusion assay in which
HIV-1 Env and T7 polymerase are expressed in HeLa cells,
while plasmids encoding CD4, the desired coreceptors, and
luciferase under control of the T7 promoter are transfected
into a target cell population (45, 49). The two cell populations
are mixed, and if cell-cell fusion occurs, luciferase is produced
as a consequence of cytoplasmic mixing. The results of a representative experiment are shown in Fig. 2. In all experiments,
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FIG. 1. Effects of CCR2b or CCR2b-V64I on HIV-1 coreceptor expression. Equal amounts of CCR2b and the V64I variant were transfected into 293T cells,
expression was allowed for 18 h, and subsequently staining was done with biotinylated anti-CCR2b antibody R02 followed by phycoerythrin-conjugated streptavidin.
FACS analysis was used to determine surface expression levels, which are presented as the MCF (A). Similarly, CCR5 (B), CXCR4 (C), or CCR3 (D) was transfected
into 293T cells alone or in combination with either CCR2b or V64I. Coreceptor expression levels were determined via FACS analysis by staining with MAbs 45549,
12G5, and 7B11 against CCR5, CXCR4 and CCR3, respectively (see Materials and Methods).
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CCR2b-V64I and CCR2b supported cell-cell fusion by the
HIV-1 89.6 Env protein equally well but at levels much lower
than what was observed with CCR5. Further, coexpression of
either CCR2b or CCR2b-V64I with CCR5, CXCR4, or CCR3
had no deleterious effects on the coreceptor activities of these
molecules when tested against either 89.6 Env (Fig. 2) or other
R5 (JR-FL) or X4 (BK132) Env proteins (data not shown).
Thus, the V64I mutation did not affect the coreceptor activity
of CCR2b, nor did it affect the activity of other HIV-1 coreceptors in transiently transfected cells.
While the cell-cell fusion assay has been used to identify the
coreceptors used by different virus strains, quantitative differences are sometimes observed between this and virus infection
assays. Therefore, to determine whether CCR2b-64I was able
to mediate entry by a virus that uses CCR2 for CD4-mediated
fusion, QT6/CD4 cells were transfected with wild-type or mutant CCR2b and infected with HIV-1 89.6, and the cell lysate
was analyzed 2 days later for the presence of specific viral DNA
sequences, using a PCR-based assay (26). As shown in Fig. 3,
both CCR2b-V64I and CCR2b supported 89.6 entry. Within
each experiment, there was often some variability in the intensity of signal with the two CCR2b variants, but these differences were slight and not reproducible. However, the intensity
of signal with CCR2b- and CCR2b-64I-mediated infection was
always markedly less than that seen in parallel wells with CCR5
(Fig. 3) or CXCR-4 (data not shown), consistent with our
earlier findings (26).
To determine if expression of CCR2b or CCR2b-V64I affected the coreceptor activity of CCR5 or CXCR4, cells were

FIG. 3. Viral entry and infection. QT6/CD4 cells were transfected with cofactor or with vector alone and the following day infected with DNase-treated
HIV-1 89.6 virus stock. Two days later, the cells were lysed and viral entry was
determined by PCR detection of viral DNA reverse transcription products, using
LTR primers, followed by Southern blotting.

cotransfected with various combinations of coreceptors and
then infected with luciferase reporter viruses bearing Env proteins known to use either CCR5 (HIV-1 ADA) or CXCR4
(HIV-1 HxB2) (15, 17). Different ratios of plasmids were used
in order to obtain equivalent levels of CCR2b and CCR2bV64I. As shown in Fig. 4, coexpression of either CCR2b or
CCR2b-V64I with CCR5 reduced, on average, infection mediated by the R5 Env protein ADA. However, the reduction
was slight and there were no statistically significant differences
between the effects seen with CCR2b and CCR2b-V64I. Likewise, there were no statistically significant differential effects of
either CCR2b or CCR2b-V64I coexpression on the use of
CXCR4 by the X4 virus strain HxB2. Taken together, these
results show that in transfected cells, the V64I mutation does
not adversely affect the coreceptor activity of CCR2b, nor does
it significantly affect the coreceptor activity of CCR5 or
CXCR4 as measured by cell-cell fusion and virus infection
assays.

FIG. 4. Coexpression of CCR2b or CCR2b-V64I with CCR5 or CXCR4 does
not affect infectability by R5 or X4 virus. CCR5 (A) or CXCR4 (B) was transfected alone or in combination with CCR2b or V64I and subsequently infected
by luciferase reporter viruses pseudotyped with the R5 ADA or the X4 HxB2
Env as indicated. Luciferase activity was measured 4 days after infection. Results
are normalized to the percentage of relative light units obtained by infection of
cells transfected with CCR5 or CXCR4 alone. Data are presented as mean 6
standard error of the mean of four independent experiments.
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FIG. 2. Fusion activity of CCR2b and V64I. 293T cells expressing the R5X4 89.6 Env protein (which also utilizes CCR2b) and T7 polymerase were mixed with quail
QT6 cells expressing CD4, the indicated coreceptor(s), and luciferase under control of the T7 promoter. Cell-cell fusion was assessed 8 h later by lysis of cells followed
by quantitation of luciferase activity in relative light units (RLU). The results shown are from a typical experiment representative of four independent experiments. The
trends observed were identical even when different effector cells (simian COS cells) and target cells (feline CCC cells) were used.
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Expression of HIV-1 coreceptors on PBMCs. While the V64I
mutation did not affect CCR2b, CCR5, or CXCR4 expression
in transfected cells, it is possible that the effects of the mutation
are evident only in primary cells. Therefore, we screened 84
individuals for the V64I mutation by PCR-RFLP analysis and
identified 13 heterozygotes (1/V64I) and 2 homozygotes
(V64I/V64I) for allelic frequencies of 0.083 for Caucasians and
0.225 for Asians, closely matching the published frequencies
from large HIV-infected cohorts (55). PBMCs were isolated
from race-matched volunteers with either CCR2b 1/1,
1/V64I, or V64I/V64I genotypes and stimulated with PHA
and IL-2. FACS analysis using antibodies to CCR2, CCR5, and
CXCR4 revealed no genotype-associated differences in expression levels on stimulated PBMCs (data not shown). However,
stimulation of PBMCs in vitro is known to elevate CCR5 receptor expression levels (59) and may also influence the ex-

TABLE 1. HIV-1 replication in CCR2b wild-type or CCR2b-V64I PBMCsa
Mean supernatant p24 antigen level (ng/ml) 6 SEM
Expt

1

2

3

IIIB

SF162

Day 7

Day 14

Day 7

Wild type
CCR2b-V64I

9.5 6 3.0
13.8 6 5.5

26.5 6 5.5
69.2 6 10.3

183 6 8.4
114 6 9.3

Wild type
CCR2b-V64I

811 6 21.6
664 6 16.6

850 6 18.5
490 6 17.5

Wild type
CCR2b-V64I

30.7 6 3.4
23.1 6 5.1

351 6 8.6
174 6 10.6

BR-2
Day 14

Day 7

Day 14

103 6 5.0
68.3 6 6.9

164 6 12.0
111 6 12.4

71.4 6 7.8
51.0 6 8.2

613 6 10.3
384 6 12.8

79.9 6 8.9
238 6 10.3

373 6 5.3
161 6 8.0

107 6 4.5
67.0 6 4.2

257 6 13.8
381 6 9.9

480 6 15.8
328 6 5.2

129 6 7.6
98.2 6 8.4

269 6 10.9
120 6 6.8

a
Equal amounts of all viruses (20 ng of p24 antigen) were used to infect PHA/IL-2-stimulated PBMCs, and supernatant p24 antigen levels were measured by
enzyme-linked immunosorbent assay. CCR2b-V64I heterozygous and homozygous donors were considered as a single group. In each experiment, cells were harvested
from two to four donors in each category and analyzed in duplicate infections.
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FIG. 5. Comparison of HIV-1 coreceptor expression on PBMCs from individuals with or without the V64I variant. Unstimulated PBMCs isolated as
described in Materials and Methods were stained and FACS analyzed for
CCR2b, CXCR4, and CCR5 expression levels. Due to the logistic difficulties of
staining fresh PBMCs for multiple coreceptors on multiple volunteers, data are
presented as compiled from several different FACS experiments. Data points
with similar symbols indicate data from a single FACS experiment performed on
the same day, with each data point representing the results obtained with cells
from a different individual. Expression levels are presented as MCF, and only
positive data points defined as being at least threefold above the MCF obtained
for the isotype-matched negative controls are presented. Solid bars indicate the
mean for each data spread. All non-Asians used for comparison studies of
coreceptor expression were screened for the D32-ccr5 allele in order to control
for the contribution of this allele to CCR5 expression levels. The Asian population in this study was not screened because the 32-ccr5 allele is nonexistent in
the Asian population (4).

pression of other chemokine receptors (40). Therefore, to control for any effects that in vitro stimulation of PBMCs might
have, we also tested unstimulated cells. Since Ficoll purification of PBMCs has been found to result in transient down
regulation of CXCR4 (56a), cells were analyzed either by direct staining of whole blood followed by selective erythrocyte
lysis or after a 6-h recovery period in medium not supplemented with either mitogen or IL-2 (see Materials and Methods). Similar results were obtained with both approaches.
While there were no differences in CCR2b expression levels
among the three genotypes, we found a mean decrease of
approximately 37% in cell surface expression levels of CXCR4
between 1/1 and 1/V64I individuals (Fig. 5). While this difference was statistically significant (P , 0.025), PBMCs from
1/V64I individuals were fully permissive to infection by X4
virus strains (see below). A slight decrease in CCR5 expression
levels was also observed in 1/V64I individuals, but this difference was not statistically significant. Finally, as only two homozygotes were identified, we can draw no conclusions about
the effects of the V64I/V64I genotype on receptor expression
levels. Examination of a larger number of individuals who bear
the CCR2b-V64I mutation will have to be performed to more
accurately determine the expression levels of the major HIV-1
coreceptors and to determine the effects of different culture
conditions and purification protocols on the cell surface expression of these molecules.
Infection of PBMCs from individuals with the CCR2b-V64I
polymorphism. To determine if the CCR2b-V64I mutation
could have any unforeseen effects on HIV-1 entry or replication in primary cells, PHA/IL-2-stimulated PBMCs from 1/1,
1/V64I, and V64I/V64I individuals were infected with equal
amounts of the X4 virus strain IIIB or the R5 virus strain
SF162 or BR-2. In each experiment, cells were harvested from
two to four donors in each category and analyzed in duplicate
experiments. Viral p24 values were measured 7 and 14 days
after infection, and the results were averaged. Results from
three independent experiments are shown in Table 1. As differences were not observed between 1/V64I and V64I/V64I
samples, these were considered as a single group. While there
was some variability, we observed no consistent differences
between the abilities of 1/V64I and V64I/V64I PBMCs to
support virus infection compared to 1/1 PBMCs. Thus, the
CCR2b-V64I polymorphism did not affect the ability of HIV-1
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DISCUSSION
Infection of cells by HIV-1 requires the presence of a coreceptor such as CCR5 or CXCR4 (reviewed in references 7, 10,
12, 23, and 43). Three naturally occurring polymorphisms that

FIG. 6. Signaling capability of CCR2b and CCR2b-V64I and effects on
CCR5 and CXCR4. (A) 293T cells cotransfected with CCR5 and either CCR2b
(top) or CCR2b-V64I (bottom). In the experiment shown, RANTES activated
CCR5, MCP-1 activated CCR2b and CCR2b-V64I, and TAP is a control agonist
for cell viability. 293T cells exhibited no background activation in response to
either RANTES or MCP-1 (data not shown). Surface expression of receptors was
monitored by FACS of parallel sets of cells and was equivalent for both sets of
cells. Cells in the right- and left-hand columns differ only in the order of chemokine stimulation. CCR2b and CCR2b-V64I responded to MCP-1 nearly identically in the experiment shown and when transfected into cells without additional coreceptors (data not shown). (B) 293T cells cotransfected with CXCR4
and CCR2b. Cells in the right- and left-hand columns differ only in their order
of chemokine stimulation. Similar results were obtained when CCR2b-V64I was
used (data not shown).

demonstrate the importance of chemokines and chemokine
receptors for HIV-1 infection in vivo have been described.
Elimination of surface expression of CCR5, caused by a 32-bp
deletion in the CCR5 open reading frame (CCR5-D32), renders homozygotes highly resistant to viral infection and delays
progression of disease in heterozygotes (20, 39, 41, 51). A
recently identified polymorphism in the 39 untranslated region
of the SDF-1b gene suggests that expression levels of this
chemokine may affect progression to disease (58). In the case
of CCR2-V64I, there is no protection against virus transmission, but individuals with a single copy of this allele progress to
AIDS 2 to 4 years more slowly than individuals without this
polymorphism (55). A subsequent study, using a seroprevalent
cohort rather than a cohort that followed individuals from the
time of seroconversion, disputed this finding (42). However,
the protective effect of the CCR2-V64I polymorphism has now
been confirmed by several groups using cohorts followed from
the time of seroconversion (37, 48, 54). Understanding how
this polymorphism results in delayed disease progression may
provide additional insight into the interplay between HIV-1,
chemokines, and chemokine receptors and may also suggest
new therapeutic strategies.
Our results indicate that the effects of the CCR2b-V64I poly-
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to productively infect PBMCs, at least for the virus strains
examined and under the tissue culture conditions used.
Asymmetric, heterologous desensitization of CCR5 and
CXCR4 by CCR2b. Our results indicate that the V64I mutation
does not directly affect CCR2b expression or its already limited
HIV-1 coreceptor capability. In addition, CCR2b-V64I did not
affect the coreceptor activity of CCR3, CCR5, or CXCR4.
These data argue that if the V64I polymorphism affects CCR3,
CCR5, or CXCR4 coreceptor function in vivo, it is unlikely to
be due to mere expression of the CCR2b-V64I receptor. However, G-protein-mediated signaling events can induce both intracellular changes that affect cellular activation and functional
changes that alter the number and state of receptors on the
surface of a cell. Peptide chemoattractant receptors have previously been reported to be capable of heterologous desensitization (limiting the signaling response of other receptors),
suggesting a cross-communication between receptors that
could affect surface expression (11, 14, 36, 56). Moreover, the
recent demonstration that HIV-1 Env can signal through
CCR5 and CXCR4 (19, 57) suggests that if this signal is important for HIV-1 replication and if other receptors have the
ability to abrogate this signal, then factors that desensitize
CCR5 or CXCR4 may protect against HIV infection. In fact,
heterologous desensitization of a RANTES response by
MCP-1 has been reported for the human monocytic leukemia
MonoMac 6 cell line (14). We therefore determined whether
the V64I mutation affected CCR2b-dependent signaling and
whether activation of CCR2b desensitized the major HIV-1
coreceptors. Addition of MCP-1 to 293T cells expressing either
CCR2b or CCR2b-V64I resulted in similar calcium mobilization profiles (Fig. 6). In addition, we found that addition of
MCP-1 to either 1/1, 1/V64I, or V64I/V64I PBMCs resulted
in similar calcium mobilization responses (data not shown).
Thus, the V64I mutation has no obvious effects on the capability of CCR2b to signal upon binding MCP-1.
To determine if CCR2b signaling could affect either of the
major HIV-1 coreceptors, 293T cells were transfected with
various combinations of CCR2b, CCR2b-V64I, CCR5, and
CXCR4. Chemokines were then added sequentially, and receptor signaling was determined by measuring calcium mobilization. Equivalent levels of chemokine receptors were ensured in these experiments by transfecting limiting amounts of
CCR2b DNA and subsequently measuring surface expression
and Ca21 mobilization in parallel sets of cells. We found that
addition of MCP-1 to cells expressing either CCR2b or
CCR2b-V64I completely desensitized subsequent signaling via
either CCR5 or CXCR4 following addition of RANTES or
SDF-1, respectively (Fig. 6). CCR2b and CCR2b-V64I functioned equally well in this regard. By contrast, prior addition of
RANTES or SDF-1 did not abrogate a subsequent signal mediated by either CCR2b or CCR2b-V64I resulting from the
addition of MCP-1. None of the chemokines tested desensitized PAR-1 (the thrombin receptor), a G-protein-coupled
receptor unrelated to the chemokine receptors, which was used
as an internal control in all experiments for cell viability. Additionally, prior signaling mediated by PAR-1 had only minor
effects on RANTES/CCR5 and SDF-1/CXCR4 signaling (data
not shown). Thus, addition of MCP-1 to cells expressing either
CCR2b or CCR2b-V64I results in the asymmetric heterologous desensitization of both major HIV-1 coreceptors.
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kine receptors to desensitize each other suggests complex
mechanisms of regulation that could potentially alter chemokine receptor signaling capability and surface expression.
Therefore, we investigated the signaling capability of CCR2bV64I and determined if it could influence the ability of other
HIV-1 coreceptors to signal.
We found that activation of both CCR2b and CCR2b-V64I
by MCP-1 resulted in the heterologous desensitization of both
CCR5 and CXCR4. Desensitization of a RANTES response by
MCP-1 was reported previously (14). Desensitization was
asymmetric, since activation of either CCR5 or CXCR4 only
minimally reduced subsequent CCR2b activation. Heterologous desensitization of other peptide chemoattractant receptors has been reported, though the mechanism by which this
occurs is not well understood (11, 14, 36, 56). It is important to
note that both CCR2b and CCR2b-V64I signaled equally well
in response to MCP-1 and that both desensitized CXCR4 and
CCR5. Thus, the ability of the CCR2b-V64I polymorphism to
desensitize the major HIV-1 coreceptors is not unique to the
mutant allele and is therefore not likely to explain its protective effect, although we cannot rule out the possibility that it
can differentially desensitize the major HIV-1 coreceptors in
vivo. In addition, any effects on other splice variants of CCR2
cannot be excluded. However, the CCR2b ligands MCP-1 and
MCP-3 have been reported to inhibit the productive infection
of PBMCs by both R5 and X4 strains of HIV-1 (32, 53). An
anti-CCR2b antibody which possesses agonist activity comparable in potency to that of MCP-1 has also been shown to
inhibit infection of PBMCs by some virus strains, although it is
interesting that other MAbs to CCR2 that do not possess such
agonist properties do not inhibit HIV (32). MCP-1 does not
block direct infection of blood dendritic cells, which express
mRNA for CCR2, CCR3, CCR5, and CXCR4, but does block
virus spread to activated lymphocytes when cocultured with
HIV-1-pulsed dendritic cells (6). Thus, the putative HIV-1suppressive effect of CCR2b ligands seems not to be at the
level of viral entry via CCR2b but appears to be exerted
through its agonist activity. The means by which these CCR2b
ligands exert their antiviral activity is not known, but our findings provide a mechanistic link between CCR2 and the major
HIV-1 coreceptors that offers a potential explanation for the
HIV-1-suppressive effect of various CCR2b ligands.
Under the conditions used, our studies failed to reveal functional differences between CCR2b and CCR2b-V64I. The mutant protein exhibited no significant differences from its wildtype CCR2 parent in either coreceptor function, chemokine
receptor function, or effect on CCR3, CCR5, or CXCR4 functions. The importance of the minor difference associated with
CXCR4 expression levels on 1/V64I unstimulated PBMCs
remains to be determined. Therefore, we consider it likely that
the mutant CCR2-V64I protein is only indirectly related to the
true protective effect associated with the polymorphism. We
cannot rule out the possibility that the mutation exerts a subtle
effect on CCR2b function that was not detected by our in vitro
assays, or that the V64I polymorphism is linked to a second,
more significant mutation in the CCR5 gene or elsewhere. In
our investigation of this polymorphism, however, we have
clearly established the ability of CCR2b, when signaled, to
cross-regulate the major HIV coreceptors CCR5 and CXCR4.
The significance of this cross-regulation for CCR5 and
CXCR4, in terms of receptor signaling, receptor expression,
and coreceptor usage, and whether these events can possibly
help explain the protective effects of the V64I polymorphism
remain to be determined.
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morphism are unlikely to be directly linked to use of CCR2b as
an HIV-1 coreceptor. Besides the fact that few viruses appear
to use CCR2b as a coreceptor (22), we found that the polymorphism had no effects on CCR2b coreceptor function for a
virus which does use this receptor (HIV-1 89.6) at the level of
either cell-cell fusion or virus infection. For these reasons, we
considered the possibility that the effects of CCR2b-V64I
would be exerted in trans on the major HIV-1 coreceptors,
CCR5 and CXCR4. However, we did not detect any differential effect of CCR2b or CCR2b-V64I expression on CCR3,
CCR5, or CXCR4 coreceptor function, as judged by both cellcell fusion and virus infection assays, nor did coexpression of
CCR2-V64I with CCR5 or CXCR4 alter their surface expression. Thus, in transfected cell lines, CCR2b and CCR2b-V64I
were indistinguishable in their influences on the expression
and activity of the major HIV-1 coreceptors.
The magnitude of the protective effect of CCR2b-V64I is
similar to that observed with a single allele of CCR5- 32.
PBMCs from individuals with a single copy of CCR5- 32 are
readily infectable by HIV-1 in vitro (47), but they do exhibit
reduced levels of CCR5 on the cell surface (59). Therefore, we
reasoned that CCR2b-V64I PBMCs might exhibit similar
properties. We found that PHA/IL-2-stimulated PBMCs from
individuals with the V64I polymorphism had normal surface
expression levels of CCR2, CCR5, and CXCR4. Since stimulation of PBMCs in culture can alter chemokine receptor expression, we also analyzed unstimulated PBMCs from CCR21/1, CCR2-1/64I, and CCR2-64I/64I individuals. Once again,
equivalent surface expression levels of CCR2 and CCR5 were
observed, though PBMCs from individuals with a single copy
of the CCR2b-V64I allele had approximately one-third less
CXCR4 on the cell surface. However, these cells were fully
permissive to infection by X4 virus strains.
Another possible explanation for the protective effect of the
CCR2b-V64I allele is that it is tracking a linked mutation
through linkage disequilibrium (55). Most C-C chemokine receptor genes are clustered together on chromosome 3, with the
CCR5 and CCR2 loci approximately 14 kb apart. While we
have not detected a mutation in the CCR5 open reading frame
that cosegregates with CCR2b-V64I, the possibility remains
that a mutation in the noncoding region of CCR5 or some
other mutation might be directly responsible for the protective
effect. Indeed, Kostrikis et al. have found that the V64I polymorphism is linked to a single-base change in the CCR5 promoter, though they did not observe differences in CCR5 expression (37). Consistent with this, our experiments with
1/V64I and V64I/V64I PBMCs indicate that differences in
CCR5 expression levels are not apparent, nor are there obvious differences in the infectability of V64I PBMCs by HIV-1 in
vitro.
While the coreceptors play a critical role in supporting entry
of HIV-1 into cells, there is some evidence that coreceptors
may also influence postentry events in virus replication (13,
28). For example, T-cell-tropic (T-tropic) strains of SIV use
CCR5 as a coreceptor which enables them to enter macrophages, yet they fail to replicate in an Env-dependent manner
(44). Differences in how macrophagetropic (M-tropic) and Ttropic SIV strains interact with CCR5 have been reported and
may help account for this difference (28). More recently, several soluble HIV-1 and SIV Env proteins have been shown to
interact with CCR5 or CXCR4 in a manner that results in
receptor signaling (19, 57). While coreceptor signaling is not
required for Env-mediated membrane fusion or virus infection
of transformed cell lines (3, 5, 24, 25, 30, 33), receptor signaling
could influence postentry events of virus replication in primary
cells such as macrophages. In addition, the ability of chemo-
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